Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

NovaBay Pharmaceuticals (NBY) Operating Expenses (2016 - 2025)

NovaBay Pharmaceuticals (NBY) has disclosed Operating Expenses for 16 consecutive years, with $1.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Operating Expenses fell 23.78% to $1.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $13.2 million, a 71.23% increase, with the full-year FY2024 number at $12.3 million, up 20.95% from a year prior.
  • Operating Expenses was $1.3 million for Q3 2025 at NovaBay Pharmaceuticals, down from $1.9 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $11.2 million in Q4 2022 to a low of $1.3 million in Q3 2025.
  • A 5-year average of $3.5 million and a median of $2.9 million in 2021 define the central range for Operating Expenses.
  • Peak YoY movement for Operating Expenses: tumbled 81.3% in 2023, then skyrocketed 220.85% in 2024.
  • NovaBay Pharmaceuticals' Operating Expenses stood at $4.9 million in 2021, then surged by 129.5% to $11.2 million in 2022, then crashed by 81.3% to $2.1 million in 2023, then surged by 220.85% to $6.7 million in 2024, then tumbled by 80.65% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for NBY's Operating Expenses are $1.3 million (Q3 2025), $1.9 million (Q2 2025), and $3.3 million (Q1 2025).